Our Pipeline

Updated on October 25 2024.

Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 78 clinical-stage projects, 32 of which are in phase 3 or have been submitted to regulatory authorities for approval. Some of these are new molecular entities while others are existing products with potential new indications, or different formulations. All of them are made possible by people who volunteer to participate in a clinical trial.

Phase 1
14
Phase 2
32
Phase 3
27
Registration
5

Changes that occurred in our R&D pipeline are detailed in our quarterly earnings press release, issued on 25 October 2024.

Search for a Specific a Clinical-Stage Project

All therapeutic areas
All phases
All expected timeline
78 project(s) of 78
Therapeutic Area
Phase
Name
Description
Indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444336

Phase

1
2
3
R

Description

Non-beta IL2 Synthorin™

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR445399

Phase

1
2
3
R

Description

IL1R3 mAb

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR445611

Phase

1
2
3
R

Description

CX3CR1 Nanobody® VHH

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR446422

Phase

1
2
3
R

Description

CD28/OX40 bispecific Ab

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb
New phase

Indication

Celiac disease

New phase

Celiac disease

New phase

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Systemic sclerosis

Systemic sclerosis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Alopecia areata

Alopecia areata

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Hidradenitis suppurativa

Hidradenitis suppurativa

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Asthma

Asthma

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4/IL13 mAb

Indication

Ulcerative colitis

Ulcerative colitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

duvakitug

Phase

1
2
3
R

Description

TL1A mAb

Indication

Crohn's disease

Crohn's disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

duvakitug

Phase

1
2
3
R

Description

TL1A mAb

Indication

Ulcerative colitis

Ulcerative colitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

eclitasertib

Phase

1
2
3
R

Description

RIPK1 inhibitor

Indication

Ulcerative colitis

Ulcerative colitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Type 1 diabetes

Type 1 diabetes

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Systemic lupus erythematosus

Systemic lupus erythematosus

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

itepekimab

Phase

1
2
3
R

Description

IL33 mAb

Indication

Bronchiectasis

Bronchiectasis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

lunsekimig

Phase

1
2
3
R

Description

IL13/TSLP Nanobody® VHH
New phase

Indication

Chronic rhinosinusitis with nasal polyps

New phase

Chronic rhinosinusitis with nasal polyps

New phase

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

lunsekimig

Phase

1
2
3
R

Description

IL13/TSLP Nanobody® VHH

Indication

Asthma

Asthma

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

riliprubart

Phase

1
2
3
R

Description

C1s inhibitor

Indication

Antibody-mediated rejection

Antibody-mediated rejection

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Chronic spontaneous urticaria

Chronic spontaneous urticaria

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Asthma

Asthma

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

IgG4-related disease

IgG4-related disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR441566

Phase

1
2
3
R

Description

Oral TNFR1 signaling inhibitor

Indication

Rheumatoid arthritis

Rheumatoid arthritis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR441566

Phase

1
2
3
R

Description

Oral TNFR1 signaling inhibitor

Indication

Psoriasis

Psoriasis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR442970

Phase

1
2
3
R

Description

TNFa/OX40L Nanobody® VHH

Indication

Hidradenitis suppurativa

Hidradenitis suppurativa

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444656

Phase

1
2
3
R

Description

IRAK4 degrader

Indication

Hidradenitis suppurativa

Hidradenitis suppurativa

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444656

Phase

1
2
3
R

Description

IRAK4 degrader

Indication

Atopic dermatitis

Atopic dermatitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Atopic dermatitis

Atopic dermatitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4/IL13 mAb

Indication

Chronic spontaneous urticaria (US)

Chronic spontaneous urticaria (US)

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4/IL13 mAb

Indication

Eosinophilic gastritis

Eosinophilic gastritis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4/IL13 mAb

Indication

Bullous pemphigoid

Bullous pemphigoid

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4/IL13 mAb

Indication

Chronic pruritis of unknown origin

Chronic pruritis of unknown origin

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

itepekimab

Phase

1
2
3
R

Description

IL33 mAb

Indication

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Rezurock

Phase

1
2
3
R

Description

ROCK2 inhibitor

Indication

1L chronic graft versus host disease

1L chronic graft versus host disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Rezurock

Phase

1
2
3
R

Description

ROCK2 inhibitor

Indication

Chronic lung allograft dysfunction

Chronic lung allograft dysfunction

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Tzield

Phase

1
2
3
R

Description

CD3 mAb

Indication

Type 1 diabetes

Type 1 diabetes

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4/IL13 mAb

Indication

Chronic obstructive pulmonary disease (JP)

Chronic obstructive pulmonary disease (JP)

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4/IL13 mAb

Indication

Chronic spontaneous urticaria (EU)

Chronic spontaneous urticaria (EU)

Therapeutic Area

Neurology

1
2
3
R

Name

SAR446159

Phase

1
2
3
R

Description

Synuclein/IGF1R mAb

Indication

Parkinson's disease

Parkinson's disease

Therapeutic Area

Neurology

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Non-relapsing secondary progressive MS

Non-relapsing secondary progressive MS

Therapeutic Area

Neurology

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Relapsing multiple sclerosis

Relapsing multiple sclerosis

Therapeutic Area

Neurology

1
2
3
R

Name

riliprubart

Phase

1
2
3
R

Description

C1s inhibitor

Indication

IVIg-treated CIDP

IVIg-treated CIDP

Therapeutic Area

Neurology

1
2
3
R

Name

riliprubart

Phase

1
2
3
R

Description

C1s inhibitor

Indication

SOC-refractory CIDP

SOC-refractory CIDP

Therapeutic Area

Neurology

1
2
3
R

Name

tolebrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Non-relapsing secondary progressive MS

Non-relapsing secondary progressive MS

Therapeutic Area

Neurology

1
2
3
R

Name

tolebrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Primary progressive MS

Primary progressive MS

Therapeutic Area

Neurology

1
2
3
R

Name

tolebrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Relapsing multiple sclerosis

Relapsing multiple sclerosis

Therapeutic Area

Oncology

1
2
3
R

Name

pegenzileukin

Phase

1
2
3
R

Description

Non-alpha IL2 Synthorin™

Indication

Cancer, in combination

Cancer, in combination

Therapeutic Area

Oncology

1
2
3
R

Name

SAR444200

Phase

1
2
3
R

Description

GPC3/TCR Nanobody® VHH

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

SAR444881

Phase

1
2
3
R

Description

ILT2 mAb

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445514

Phase

1
2
3
R

Description

Trifunctional anti-BCMA NK cell engager

Indication

Relapsed/refractory multiple myeloma

Relapsed/refractory multiple myeloma

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445877

Phase

1
2
3
R

Description

PD1/IL15 fusion protein

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445953

Phase

1
2
3
R

Description

CEACAM5/Topo1 ADC

Indication

Colorectal cancer

Colorectal cancer

Therapeutic Area

Oncology

1
2
3
R

Name

SAR443579

Phase

1
2
3
R

Description

Trifunctional anti-CD123 NK cell engager

Indication

Acute myeloid leukemia

Acute myeloid leukemia

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb

Indication

Multiple myeloma, relapsed/refractory

Multiple myeloma, relapsed/refractory

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb

Indication

Multiple myeloma, 1L TE (IsKia)

Multiple myeloma, 1L TE (IsKia)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb subcutaneous

Indication

Multiple myeloma, relapsed/refractory (IRAKLIA)

Multiple myeloma, relapsed/refractory (IRAKLIA)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb

Indication

Smoldering multiple myeloma (ITHACA)

Smoldering multiple myeloma (ITHACA)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb

Indication

Multiple myeloma, 1L TE (HD7)

Multiple myeloma, 1L TE (HD7)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb

Indication

Myélome multiple, 1L TI (IMROZ) (EU, JP, CN)

Myélome multiple, 1L TI (IMROZ) (EU, JP, CN)

Therapeutic Area

Rare Diseases

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Warm autoimmune hemolytic anemia

Warm autoimmune hemolytic anemia

Therapeutic Area

Rare Diseases

1
2
3
R

Name

SAR447537

Phase

1
2
3
R

Description

AAT fusion protein

Indication

Alpha-1 antitrypsin deficiency

Alpha-1 antitrypsin deficiency

Therapeutic Area

Rare Diseases

1
2
3
R

Name

Nexviazyme

Phase

1
2
3
R

Description

Enzyme replacement therapy

Indication

Pompe disease, infantile onset (US)

Pompe disease, infantile onset (US)

Therapeutic Area

Rare Diseases

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Immune thrombocytopenia

Immune thrombocytopenia

Therapeutic Area

Rare Diseases

1
2
3
R

Name

venglustat

Phase

1
2
3
R

Description

Oral GCS inhibitor

Indication

Fabry disease

Fabry disease

Therapeutic Area

Rare Diseases

1
2
3
R

Name

venglustat

Phase

1
2
3
R

Description

Oral GCS inhibitor

Indication

Gaucher disease type 3

Gaucher disease type 3

Therapeutic Area

Rare Diseases

1
2
3
R

Name

fitusiran

Phase

1
2
3
R

Description

RNAi targeting anti-thrombin

Indication

Hemophilia A and B (US, CN)

Hemophilia A and B (US, CN)

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0237

Phase

1
2
3
R

Description

Flu mRNA vaccine

Indication

Flu

Flu

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0256

Phase

1
2
3
R

Description

hMPV/RSV mRNA vaccine

Indication

hMPV/RSV older adults

hMPV/RSV older adults

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0268

Phase

1
2
3
R

Description

Acne mRNA vaccine

Indication

Acne

Acne

Therapeutic Area

Vaccines

1
2
3
R

Name

Fluzone HD

Phase

1
2
3
R

Description

Influenza inactivated vaccine

Indication

Flu, pediatric

Flu, pediatric

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0202

Phase

1
2
3
R

Description

Pneumococcal 21-valent conjugate vaccine

Indication

Pneumococcal disease

Pneumococcal disease

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0218

Phase

1
2
3
R

Description

Yellow fever vero cell vaccine

Indication

Yellow fever

Yellow fever

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0230

Phase

1
2
3
R

Description

Pentavalent meningococcal ABCWY conjugate vaccine

Indication

Meningitis

Meningitis

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0256

Phase

1
2
3
R

Description

RSV mRNA vaccine

Indication

RSV older adult

RSV older adult

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0087

Phase

1
2
3
R

Description

Rabies vero cell vaccine

Indication

Rabies

Rabies

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0125

Phase

1
2
3
R

Description

RSV live attenuated vaccine

Indication

Respiratory syncytial virus (toddler)

Respiratory syncytial virus (toddler)

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0282

Phase

1
2
3
R

Description

Extraintestinal Pathogenic E. Coli 9-valent vaccine (ExPEC9V)

Indication

E. coli sepsis

E. coli sepsis

Therapeutic Area

Vaccines

1
2
3
R

Name

MenQuadfi

Phase

1
2
3
R

Description

Meningococcal ACYW conjugate vaccine
New phase

Indication

Meningitis six weeks+ (US)

New phase

Meningitis six weeks+ (US)

New phase

Related Links

Research & Development

See more

Technology Platforms

See more

Clinical trials & results

See more